Case report: reinitiating pembrolizumab treatment after small bowel perforation

BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as paradigm shifting treatment options for a number of cancers. Six antibodies targeting the immune checkpoint proteins programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) or cytotoxic T-lymphocyte associated protein 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Tim N., Kudinov, Alexander E., Dulaimi, Essel, Boumber, Yanis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482547/
https://www.ncbi.nlm.nih.gov/pubmed/31018834
http://dx.doi.org/10.1186/s12885-019-5577-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482547/
https://www.ncbi.nlm.nih.gov/pubmed/31018834
http://dx.doi.org/10.1186/s12885-019-5577-5

Ejemplares similares